| Dr Gregg Harry Wilding, MD | |
|
600 W Hospital Rd, Brigham City, UT 84302-3006 | |
| (435) 734-2041 | |
| (435) 723-8028 |
| Full Name | Dr Gregg Harry Wilding |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 600 W Hospital Rd, Brigham City, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881705424 | NPI | - | NPPES |
| 04202 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 151559-1205 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregg Harry Wilding, MD Po Box 719, Brigham City, UT 84302-0719 Ph: (435) 734-2041 | Dr Gregg Harry Wilding, MD 600 W Hospital Rd, Brigham City, UT 84302-3006 Ph: (435) 734-2041 |
News Archive
ImThera Medical, Inc. announced today that it has completed development of its Targeted Hypoglossal Neurostimulation (THN) system for Obstructive Sleep Apnea (OSA).
The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.
Patients with chronic gum disease who quit smoking in addition to undergoing nonsurgical therapy not only demonstrated a lower abundance of harmful oral pathogens, but also an increase in health-associated bacteria. The researchers from The Ohio State University, Columbus Ohio, and Newcastle University, United Kingdom report their findings in the July 2010 issue of the Journal of Clinical Microbiology.
Isogenica Ltd today announced that it has entered into an agreement with Australian based biopharmaceutical company Phylogica to use Isogenica's CIS display technology to optimize the performance of three of Phylogica's lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases, such as Rheumatoid Arthritis and Inflammatory Bowel Disease.
› Verified 1 days ago
Dr. Jeffrey R Lish, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 984 Medical Dr Ste 1, Brigham City, UT 84302 Phone: 435-723-5248 Fax: 877-395-5866 | |
Tye B Harrison, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 W Hospital Rd, Brigham City, UT 84302 Phone: 435-734-2041 Fax: 435-723-8028 | |
Dr. Thomas Michael Matthews, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 600 W Hospital Rd, Brigham City, UT 84302 Phone: 435-734-2041 Fax: 435-723-8028 | |
Scott Mitchell Nagao, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 984 Medical Dr Ste 1, Brigham City, UT 84302 Phone: 435-723-5248 | |
Dr. James Robert Taylor, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 600 W Hospital Rd, Brigham City, UT 84302 Phone: 435-734-2041 Fax: 435-723-8028 | |
Dr. Michael C Shaw, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 984 Medical Dr Ste 1, Brigham City, UT 84302 Phone: 435-723-5248 Fax: 435-723-5240 | |
Dr. Brian C Dawson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 984 Medical Dr Ste 1, Brigham City, UT 84302 Phone: 435-723-5248 Fax: 435-723-5240 |